Adaptive Biotechnologies (ADPT) Equity Average (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Equity Average data on file, last reported at $217.6 million in Q1 2026.

• Quarterly Equity Average rose 10.8% year-over-year to $217.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $217.6 million (up 10.8% YoY) and the FY2025 annual result came in at $210.6 million, down 17.52% from the prior year.
• Equity Average improved to $217.6 million in Q1 2026 per ADPT's latest filing, from $211.6 million in the prior quarter.
• The five-year high for Equity Average was $578.7 million in Q1 2022, with the low at $184.9 million in Q2 2025.
• Average Equity Average over 5 years is $332.9 million, with a median of $291.5 million recorded in 2024.
• Year-over-year, Equity Average tumbled 38.62% in 2024 and increased 10.8% in 2026.
• Adaptive Biotechnologies' Equity Average stood at $476.0 million in 2022, then declined by 29.62% to $335.0 million in 2023, then tumbled by 36.4% to $213.0 million in 2024, then dropped by 0.66% to $211.6 million in 2025, then advanced by 2.81% to $217.6 million in 2026.
• Business Quant data shows ADPT's Equity Average at $217.6 million in Q1 2026, $211.6 million in Q4 2025, and $192.0 million in Q3 2025.